Leading global suppliers of value-added plastic administration systems for the pharmaceutical industry.
Montagu completed the acquisition of Rexam’s Healthcare Devices and Prescription Retail divisions in May 2014. Shortly after the acquisition Healthcare Devices was renamed “Nemera” and Prescription Retail called “Centor”. With combined sales of over $435m and 1500 FTEs, both Nemera and Centor are reference suppliers in their markets.
Nemera, headquartered in La Verpillière (France), is a leading European manufacturer of plastic drug administration systems for the pharmaceutical industry. It designs, produces and sells a broad range of complex medical devices including inhalers, insulin pens and pumps. Part of the current Nemera perimeter was formed when Rexam acquired Risdon Pharma from Montagu in 2003. During the last decade, the company has developed rapidly, driven by continued focus on R&D, innovation and manufacturing excellence. In addition, targeted acquisitions expanded its geographical reach and product portfolio.
Based in Berlin (Ohio), Centor provides plastic vials and closures used by pharmacies in the US to deliver the exact count of pills to patients. It manufactures more than 1.5 billion vials annually and owns markets leading products such as "1-Clic" and "Screw-Loc". The company is the clear leader in the US prescription retail market, where it has developed strong relationships with its clients over the past decades.
Both develop and manufacture must-have products for patients on a global basis. They operate on fundamentally growing markets due to the rising prevalence of chronic diseases such as diabetes, broader access to Healthcare in emerging markets, and population ageing. Nemera and Centor benefit from entrenched competitive positions, protected by tight regulatory constraints (such as health authority approvals), and quality standards in the pharmaceutical industry.
Montagu was also attracted by the opportunity to partner with a management team we know well from our earlier successful investment in Risdon Pharma (sold in 2003). Together, we intend to extend the companies’ impressive track record of growth through increased investments in innovation and state of the art production.